FDA Approves Janssen's Stelara for Pediatric Colitis Use

Janssen Biotech's ustekinumab approval for pediatric ulcerative colitis signals a replicable regulatory pathway for sponsors holding adult biologic approvals who are seeking to extend indications to paediatric populations without de novo efficacy trials. The FDA granted the approval on the basis of a data package that combined adult UC efficacy evidence with paediatric pharmacokinetic and safety data, a construct increasingly favoured under 21 CFR Part 314 Subpart I extrapolation principles.

The approved indication covers moderately to severely active UC in patients aged 2 years and older. The evidentiary foundation rested on three pillars: adequate and well-controlled adult UC studies, PK and safety data from paediatric Crohn's disease patients aged 2 to 17, and a dedicated 52-week study enrolling 112 paediatric UC subjects aged 3 to 17. That last dataset provided the confirmatory safety and efficacy anchor the agency required before extending the label downward in age.

For regulatory affairs leads, the approval architecture is instructive. The agency accepted bridging from a related paediatric IBD population, Crohn's disease, to support the UC filing, provided the sponsor supplied condition-specific PK modelling and an adequately powered UC-specific paediatric study. Sponsors with existing adult biologics targeting inflammatory pathways should map this sequence against their own paediatric investigation plans and assess whether analogous bridging arguments are defensible under their molecule's mechanism.

The Orphan Drug Designation attached to this indication carries manufacturing and labelling consequences that QA and regulatory operations teams should not treat as administrative formality. Orphan status triggers specific post-marketing commitments, potential changes to annual product review scope, and labelling provisions under 21 CFR Part 316 that must be reflected in the approved package insert and any site-level batch documentation referencing the indication. Plants supplying paediatric formulations will also need to confirm that existing process validation covers the dose ranges and presentations appropriate for patients as young as 2 years.

Ustekinumab is now the first approved therapeutic monoclonal antibody not targeting TNF-alpha indicated for both principal forms of paediatric IBD, following the April 2026 paediatric Crohn's disease approval. The most commonly reported adverse reactions in the paediatric UC population, nasopharyngitis, headache, abdominal pain, influenza, and fever, are consistent with the established adult safety profile, a finding that will inform benefit-risk language in labelling updates and pharmacovigilance protocols.

The 52-week paediatric UC study dataset, covering 112 subjects, represents the measurable outcome against which post-approval paediatric safety reporting obligations will be benchmarked.

Source: U.S. Food and Drug Administration, What's New: Drugs RSS Feed, 28 August 2026.